Jianqiu Wu

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen et al. · Clinical Cancer Research · 2019 · 157 citations

Medicine, Oncology, Pharmacology +17

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

Zhitao Ying, Haiyan Yang, Ye Guo et al. · Cancer Medicine · 2020 · 100 citations · Full text

Medicine, Clinical Pharmacokinetics, Oncology +17

Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma

Yuxin Du, Yun Cai, Yan Lv et al. · Cancer Letters · 2022 · 71 citations · Full text

Life Sciences, Cancer Biology, Immunology +17

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Yuankai Shi, Jianqiu Wu, Zhen Wang et al. · Journal of Hematology & Oncology · 2021 · 63 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Xinhua Wang, Lei Zhang, Xiangli Liu et al. · JAMA Oncology · 2022 · 58 citations · Full text

Medicine, Oncology, Pharmacology +13